# Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

> **NCT01309945** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 889 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Duloxetine
- **DRUG:** Placebo matching with BMS-820836
- **DRUG:** BMS-820836
- **DRUG:** Duloxetine
- **DRUG:** Placebo matching with Duloxetine

## Key facts

- **NCT ID:** NCT01309945
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 889 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01309945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01309945, "Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01309945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*